Evaluation of the benefit of using blue dye in addition to indocyanine green fluorescence for sentinel lymph node biopsy in patients with breast cancer

World Journal of Surgical Oncology

Meng Tong²  Jintao Liu²  Wei Gao²  Jun Ji¹  Li Zhang¹  Wenbin Guo² 

[1] The Central Laboratory, Dalian Central Hospital, Dalian Medical University, 826, Xinan Road, Shahekou District, Dalian 116033, China;The Breast Centre, Department of Surgery, Dalian Central Hospital, Dalian Medical University, 826, Xinan Road, Shahekou District, Dalian 116033, China

关键词: Blue dye;    Fluorescence imaging;    Indocyanine green;    Breast cancer;    Sentinel lymph node biopsy;   

Others  :  1148003
DOI  :  10.1186/1477-7819-12-290

 received in 2014-01-26, accepted in 2014-09-08,  发布年份 2014

【 摘 要 】

Background

Near infrared-guided indocyanine green (ICG) fluorescence has vast potential for guiding sentinel lymph node biopsy (SLNB) in patients with breast cancer. The purpose of this study was to evaluate any additional clinical benefit for SLNB when blue dye is used in combination with ICG.

Methods

Between November of 2009 and September of 2013, 86 patients diagnosed with breast cancer were investigated by SLNB using a combination of patent blue and ICG. A lymph node was considered as the sentinel lymph node (SLN) when it was stained with blue dye and/or fluorescence. A levelIandIIaxillary dissection was performed for verification of axillary node status after the SLNB.

Results

The SLN identification rate of SLN for ICG-patent blue combination was comparable to that for ICG alone (98.8% versus 93%; P = 0.054), but the false-negative rate was reduced from 12% (3/25) to 4% (1/25). Twenty-four patients had positive SLNs. In two of those patients, although there were SLNs identified by both tracers, the positive SLNs were identified by blue dye only.

Conclusion

Although blue dye did not improve the identification rate significantly, there was a definite benefit in improving the false-negative rate. The use of a fluorescence method together with blue dye is an ideal method for hospitals that do not have access to conventional radiation-based detection methods.

【 授权许可】

   
2014 Guo et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, Yiangou C, Horgan K, Bundred N, Monypenny I, England D, Sibbering M, Abdullah TI, Barr L, Chetty U, Sinnett DH, Fleissig A, Clarke D, Ell PJ: Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 2006, 98:599-609.
• [2]Straver ME, Meijnen P, van Tienhoven G, van de Velde CJ, Mansel RE, Bogaerts J, Duez N, Cataliotti L, Klinkenbijl JH, Westenberg HA, van der Mijle H, Snoj M, Hurkmans C, Rutgers EJ: Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 Amaros trial. Ann Surg Oncol 2010, 17:185-191.
• [3]Erb KM, Julian TB: Completion of axillary dissection for a positive sentinel node: necessary or not? Curr Oncol Rep 2009, 11:15-20. Review
• [4]Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, McCall LM, Morrow M: Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011, 305:569-575.
• [5]Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, Ashikaga T, Weaver DL, Mamounas EP, Jalovec LM, Frazier TG, Noyes RD, Robidoux A, Scarth HM, Wolmark N: Preliminary technical results of NSABP B-32, a randomized phase β clinical trial to compare sentinel node resection to conventional axillary dissection in clinical node negative breast cancer patients. Breast Cancer Res Treat 2004, 88:511-512.
• [6]Wang L, Yu JM, Wang YS, Zuo WS, Gao Y, Fan J, Li JY, Hu XD, Chen ML, Yang GR, Zhou ZB, Liu YS, Li YQ, Liu YB, Zhao T, Chen P: Preoperative lymphoscintigraphy predicts the successful identification but is not necessary in sentinel lymph nodes biopsy in breast cancer. Ann Surg Oncol 2007, 14:2215-2220.
• [7]Noguchi M, Inokuchi M, Zen Y: Complement of peritumoral and subareolar injection in breast cancer sentinel lymph node biopsy. J Surg Oncol 2009, 100:100-105.
• [8]Christine B, Teal MD, Jennifer P: Evaluation of the benefit of using blue dye in addition to radioisotope for sentinel lymph node biopsy in patients with breast cancer. Breast J 2005, 6:391-393.
• [9]Sandrucci S, Casalegno PS, Percivale P, Mistrangelo M, Bombardieri E, Bertoglio S: Sentinel lymph node mapping and biopsy for breast cancer: a review of the literature relative to 4791 procedures. Tumori 1999, 85:425-434.
• [10]Stratmann SL, McCarty TM, Kuhn JA: Radiation safety with breast sentinel node biopsy. Am J Surg 1999, 178:454-457.
• [11]Sardi A, Spiegler E, Colandrea J, Frishberg D, Sing H, Regan P, Totoonchie A, Merchant D, Hochuli S, Setya V, Singer JA: The benefit of using two techniques for sentinel lymph node mapping in breast cancer. Am J Surg 2002, 68:24-28.
• [12]Ueno H, Hihara J, Shimizu K, Osaki A, Yamashita Y, Yoshida K, Toge T: Experiment study on fluorescent microspheres as a tracer for sentinel node detection. Anticancer Res 2005, 25:821-825.
• [13]Murawa D, Hirche C, Dresel S, Hünerbein M: Sentinel lymph node biopsy in breast cancer guided by indocyanine green fluorescence. Br J Surg 2009, 96:1289-1294.
• [14]Doubrovsky A, De Wilt JH, Scolyer RA, McCarthy WH, Thompson JF: Sentinel node biopsy provides more accurate staging than elective lymph node dissection in patients with cutaneous melanoma. Ann Surg Oncol 2004, 15:829-836.
• [15]Xing Y, Foy M, Cox DD, Kuerer HM, Hunt KK, Cormier JN: Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg 2006, 93:539-546.
• [16]Derossis AM, Fey J, Yeung H, Yeh SD, Heerdt AS, Petrek J, VanZee KJ, Montgomery LL, Borgen PI, Cody HS 3rd: A trend analysis of the relative value of blue dye and isotope location in 2000 consecutive cases of sentinel node biopsy for breast cancer. J Am Coll Sug 2001, 193:473-478.
• [17]McMasters KM, Wong SL, RCGMartin II, Chao C, Tuttle TM, Noyes RD, Carlson DJ, Laidley AL, McGlothin TQ, Ley PB, Brown CM, Glaser RL, Pennington RE, Turk PS, Simpson D, Cerrito PB, Edwards MJ: Dermal injection of radioactive colloid is superior to peritumoral injection for breast cancer sentinel lymph node biopsy: results of a multi-institutional study. Ann Surg 2001, 233:676-687.
• [18]Hung WK, Chan CM, Ying M, Chong SF, Mak KL, Yip AW: Randomized clinical trial comparing blue dye with combined dye and isotope for sentinel lymph node biopsy in breast cancer. Br J Surg 2005, 92:1494-1497.
• [19]Kang SW, Chung SE, Shin WJ, Lee JH: Polypoidal choroidal vasculopathy and late geographic hyperfluorescence on indocyanine green angiography. Br J Ophthalmol 2009, 93:759-764.
• [20]Schneider PD: Preoperative assessment of liver function. Surg Clin North Am 2004, 84:355-373.
• [21]Kitai T, Inomoto T, Miwa M, Shikayama T: Fluorescence navigation with indocyanine green for detecting sentinel lymph nodes in breast cancer. Breast Cancer 2005, 12:211-215.
• [22]Tagaya N, Yamazaki R, Nakagawa A, Abe A, Hamada K, Kubota K, Oyama T: Intraoperative identification of sentinel lymph nodes by near-infrared fluorescence imaging in patients with breast cancer. Am J Surg 2008, 195:850-853.
• [23]Hirche C, Murawa D, Mohr Z, Kneif S, Hünerbein M: ICG fluorescence-guided sentinel node biopsy for axillary nodal staging in breast cancer. Breast Cancer Res Treat 2010, 121:373-378.
• [24]Takeuchi M, Sugie T, Abdelazeem K, Kato H, Shinkura N, Takada M, Yamashiro H, Ueno T, Toi M: Lymphatic mapping with fluorescence navigation using indocyanine green and axillary surgery in patients with primary breast cancer. Breast 2012, 6:535-541.
• [25]Bass SS, Cox CE, Reintgen DS: Learning curves and certification for breast cancer lymphatic mapping. Surg Oncol Clin Am 1999, 8:497-509.
• [26]Dupont E, Cox C, Shivers S, Salud C, Nguyen K, Cantor A, Reintgen D: Learning curves and breast cancer lymphatic mapping: institutional volume index. J Surg Res 2001, 97:92-96.
• [27]Sanidas EE, de Bree E, Tsififif DD: How many cases are enough for accreditation in sentinel lymph node biopsy in breast cancer? Am J Surg 2003, 185:202-210.
• [28]Aoyama K, Kamio T, Ohchi T, Nishizawa M, Kameoka S: Sentinel lymph node biopsy for breast cancer patients using navigation with indocyanine green. World J Surg Oncol 2001, 9:157.